Xinhel Biosciences Secures Fourth Consecutive Spot on 'Future Healthcare 100' List, Spearheading Growth in the RNA Therapeutics Sector Amid IPO Filing

May 13, 2025 15:23 CST Updated 15:23

NeoCura

RNA Innovative Drug Developer

On May 9-10, the 2025 Future Healthcare and Pharmaceutical 100 Strong Exhibition (2025VBEF), hosted by Vbdata, was held in Suzhou. Under the theme of "THE NOW Tipping Point," the conference invited more than 300 guests to share insights, focusing on hot topics, deeply analyzing cutting-edge technologies and market trends, and exploring new opportunities for the future of healthcare.

The 2025 Future Healthcare 100 was重磅 released during the conference.NeoCura, as a pioneer in the RNA innovative drug field, has once again been honored on the "Top 100 List of China's Innovative Pharmaceuticals and Biologics."

The Future Healthcare 100 evaluation is regarded as one of the authoritative assessment systems in China's healthcare innovation field, committed to discovering and recognizing Chinese innovative pioneers who are leading the trend of the future healthcare industry development, and accelerating the pace of innovation and reform in the healthcare industry.

The evaluation criteria for this year's selection are based on the growth and annual performance in aspects such as corporate valuation, human resources, intellectual resources, key partner resources, and market performance. After three rounds of strict selection, the final list of awardees was determined.NeoCura has been ranked on the "Future Healthcare 100 Strong" list for four consecutive years, injecting strong momentum into the industry with its consistently leading innovation capabilities, commercial potential, and market influence.

In recent years, China's strategic support for the innovative drug industry has continued to strengthen, with both policies and funding working in tandem to revitalize the innovative drug market. Groundbreaking innovations are rapidly being translated into clinical applications. NeoCura, having deeply invested in the RNA innovative drug field for many years, has received CDE acceptance for the IND application of its self-developed mRNA personalized tumor neoantigen vaccine, which leverages AI technology. The company is now fully committed to advancing the commercialization process of personalized tumor neoantigen vaccines.

At the same time, the innovative drug industry is at a critical juncture of accelerated transformation. Innovation capabilities and technological barriers have become fundamental factors determining the success or failure of enterprises. NeoCura has innovatively iterated its dual-driven technology platform of AI + RNA, establishing a full-chain technological barrier from target discovery to production processes. Currently, the core technology has accumulated over a hundred patent applications both in China and internationally, covering important aspects such as neoantigen prediction, RNA sequence optimization, and delivery system screening, providing robust technical support for the development of mRNA tumor neoantigen vaccines.

The tide of innovation surges forward, and every innovator is like a fearless surfer, accumulating tremendous transformative power in the minutest details and moving ahead with courage and resolution. In the future, NeoCura will always adhere to the mission of "Pharmaceutical innovation makes life better," using AI technology as a powerful engine to accelerate the clinical translation of RNA-based innovative oncology drugs, allowing cutting-edge innovations to benefit more patients as soon as possible.

More content click "Read Original" below

Previous Recommendations

Creating Value Across Cycles | NeoCura Ranks Among "Top 10 Innovative Seed Companies in Pharmaceutical Innovation Qipu List 2024"

NeoCura Once Again Ranked in the "Top 100 Future Healthcare Companies" List for the Third Time, Leading the New Future of RNA Innovative Drug Industry

NeoCura Selected as One of the "Top 30 Supernova Enterprises," Shining with Innovation and Leading the Future of Health!

NeoCura is a national high-tech enterprise that relies on AI technology to build an RNA R&D platform and conduct innovative drug research. The company has established a multi-omics big data collection platform and multiple bio-omics databases, utilizing AI and bioinformatics technologies for in-depth drug target discovery and fully automated drug design, aimed at upgrading its innovative RNA technology platform and advancing drug research. It has set up leading R&D and production centers in Beijing, Shenzhen, and Guangzhou, China, to support pipeline R&D, platform upgrades, and clinical needs.